EU/3/18/2053

About

On 31 July 2018, orphan designation (EU/3/18/2053) was granted by the European Commission to Lakeside Regulatory Consulting Services Ltd, United Kingdom, for tamibarotene for the treatment of acute myeloid leukaemia.

Key facts

Active substance
Tamibarotene
Disease / condition
Treatment of acute myeloid leukaemia
Date of decision
31/07/2018
Outcome
Positive
Orphan decision number
EU/3/18/2053

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Lakeside Regulatory Consulting Services Ltd
20 Lakeside
Aylesbury
Bucks HP19 0FX
United Kingdom
Telephone: +44 7841026283
Telefax: +44 1296 394276
E-mail: LakesideRCS@aol.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating